Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

Published in:

Breast Cancer Research & Treatment, 2018, v. 169, n. 3, p. 537, doi. 10.1007/s10549-018-4713-2

By:

• Wagner, Lynne I.;
• Zhao, Fengmin;
• Goss, Paul E.;
• Chapman, Judith-Anne W.;
• Shepherd, Lois E.;
• Whelan, Timothy J.;
• Mattar, Bassam I.;
• Bufill, Jose A.;
• Schultz, William C.;
• LaFrancis, Irving E.;
• Nagargoje, Gauri G.;
• Vemuri, Radhakrishna;
• Nikcevich, Daniel A.;
• Sledge, George W.;
• Cella, David

Publication type:

Article